title: Safety and efficacy of Qingre Buyi Decoction in the treatment of acute radiation proctitis: a prospective, randomized and controlled trial.
abstract: OBJECTIVE
  To investigate the efficiency, safety, and possible mechanisms of Qingre Buyi Decoction (QBD) in the treatment of acute radiation proctitis (ARP).
  
  
  METHODS
  This study was a single center, prospective, single blind, randomized, and placebo-controlled clinical trial. A total of 60 patients with ARP was equally and randomly distributed into the control group (conventional treatment) and the combination group (conventional treatment plus QBD). The changes of main Chinese medicine clinical symptoms and signs, including stomachache, diarrhea, mucous or bloody stool before and after treatment, and their adverse reactions were observed after the two-week treatment. Also, D-lactate and diamine oxidase (DAO) levels, hepatic and renal function were measured. Cure rates, effective rates, and recurrence rates were compared between the two groups.
  
  
  RESULTS
  The blood levels of both DAO and D-lactate were significantly decreased in the combination group as compared with those in the control group (P<0.05 or P<0.01). All main clinical symptoms and signs were alleviated more significantly in the combination group (P<0.01). The main symptom scores also were significantly decreased after treatment in the control group (P<0.01), except those for mucous or bloody stool (P>0.05). Compared to the control group, the improvements of stomachache, diarrhea, defecation dysfunction, and stool blood in the combination group were significantly better (P<0.05 or P<0.01). For the combination group, the curative rate, effective rate, and recurrence rate was 76.67%, 16.67%, and 6.67%, respectively. On the other hand, for the control group, the rate was 53.33%, 16.67%, and 30.00%, respectively. The total curative effect was significantly better in the combination group than in the control group (P<0.05). However, the recurrence rate was similar between the two groups (P>0.05). The hepatic and renal function remained normal in both groups (P>0.05). In addition, no severe adverse event was found in both groups.
  
  
  CONCLUSIONS
  Addition of QBD to the conventional treatment can effectively alleviate the damage of intestinal mucosal barrier function and improve all main clinical symptoms and signs of the ARP. The combination of conventional treatment with Chinese herbal medicine QBD is effective and safe for ARP.
authors.affiliation: Research Institute of General Surgery, Fuzhou General Hospital, Fuzhou, 350025, China.
authors.forename: Lie
authors.initials: L
authors.lastname: Wang
authors.forename: Zai-zhong
authors.initials: ZZ
authors.lastname: Zhang
authors.forename: Xiao-huang
authors.initials: XH
authors.lastname: Tu
authors.forename: Zhong-dong
authors.initials: ZD
authors.lastname: Zou
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Liu
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D052176:Azulenes / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage; D005973:Glutamine / Q000008:administration & dosage; D006801:Humans; D055048:Integrative Medicine / Q000379:methods; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000008:administration & dosage; D010146:Pain / Q000150:complications; D011349:Proctitis / Q000150:complications / Q000188:drug therapy*; D012717:Sesquiterpenes / Q000008:administration & dosage; D017640:Silicates / Q000008:administration & dosage; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D052176:Azulenes; D004365:Drugs, Chinese Herbal; D005765:Gastrointestinal Agents; D012717:Sesquiterpenes; D017640:Silicates; C545317:qingre buyi; D005973:Glutamine; C035058:azulene SN; C033214:Smectite; D009643:Norfloxacin
references.citation: Eur J Vasc Endovasc Surg. 2006 May;31(5):470-4
references.pmid: 16376117
references.citation: Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):58-61
references.pmid: 14969839
references.citation: Lancet. 2000 Oct 7;356(9237):1232-5
references.pmid: 11072942
references.citation: Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):628-35
references.pmid: 11597802
references.citation: Strahlenther Onkol. 2003 Jul;179(7):464-70
references.pmid: 12835883
references.citation: World J Gastroenterol. 2002 Feb;8(1):168-71
references.pmid: 11833096
references.citation: Ann Surg. 2004 Apr;239(4):510-7
references.pmid: 15024312
references.citation: Clin Oncol (R Coll Radiol). 2005 Sep;17(6):485-91
references.pmid: 16149294
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1483-7
references.pmid: 16099600
references.citation: World J Gastroenterol. 2006 Aug 14;12(30):4879-83
references.pmid: 16937473